

NCI Funding Opportunities in Implementation Science

*Gila Neta, PhD MPP
Program Director, Implementation Science
Division of Cancer Control and Population Sciences*

Overview

1. *Trans-NIH D&I Funding Opportunities*
2. *NCI-Specific Opportunities and Priorities*

Trans-NIH Funding Opportunities

R01, Dissemination and Implementation Research in Health (PAR-19-274, Clinical Trial Optional)

This funding opportunity provides research project grants to support discrete, specified research projects led by an investigator in a topic area representing his or her specific interests and competencies. Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. Applications may not exceed 5 years.

R21, Dissemination and Implementation Research in Health (PAR-19-275, Clinical Trial Optional)

This funding opportunity provides grants that are intended to encourage exploratory or developmental research projects by supporting the development of pilot projects or feasibility studies to support creative, novel, and high-risk/high-payoff research. Applicants may request a project period of up to 2 years and the combined budget for direct costs may not exceed \$275,000.

R03, Dissemination and Implementation Research in Health (PAR-19-276, Clinical Trial Not Allowed)

This funding opportunity provides small research grants to support the initiation of studies that are generally for preliminary short-term projects. Applicants for an R03 award may request a project period of up to 2 years and a budget for direct costs of up to \$50,000 per year. While the grant is nonrenewable, there is less competition for these start-up research project funds.

Successful Grant Applications



Reference excerpts from successfully funded research grant applications to help prepare applications for NCI funding.

[SAMPLE GRANT APPLICATIONS](#)

Funding Inquiry Staff Contact



[Gila Neta, PhD, MPP](#)

Program Officer

netagil@mail.nih.gov

Department of Health and Human Services

Part 1. Overview Information

Participating Organization(s)

National Institutes of Health (NIH)

Components of Participating Organizations

National Cancer Institute (NCI)
 National Heart, Lung, and Blood Institute (NHLBI)
 National Human Genome Research Institute (NHGRI)
 National Institute on Aging (NIA)
 National Institute on Alcohol Abuse and Alcoholism (NIAAA)
 National Institute of Allergy and Infectious Diseases (NIAID)
 National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
 Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
 National Institute on Deafness and Other Communication Disorders (NIDCD)
 National Institute of Dental and Craniofacial Research (NIDCR)
 National Institute on Drug Abuse (NIDA)
 National Institute of Environmental Health Sciences (NIEHS)
 National Institute of Mental Health (NIMH)
 National Institute of Neurological Disorders and Stroke (NINDS)
 National Institute of Nursing Research (NINR)
 National Institute on Minority Health and Health Disparities (NIMHD)
 National Center for Complementary and Integrative Health (NCCIH)

All applications to this funding opportunity announcement should fall within the mission of the Institutes/Centers. The following NIH Offices may co-fund applications assigned to those Institutes/Centers.

Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention (ODP)
 Office of Behavioral and Social Sciences Research (OBSSR)
 Office of Research on Women's Health (ORWH)

Funding Opportunity Title

Dissemination and Implementation Research in Health (R01 Clinical Trial Optional)

Activity Code

R01 Research Project Grant

Announcement Type

Reissue of [PAR-18-007](#)

Related Notices

See [Notices of Special Interest](#) associated with this funding opportunity

- **February 19, 2021** - Notice of NIDDK Participation in PAR-19-274. See Notice [NOT-DK-21-013](#).
- **April 27, 2020** - Notice of Special Interest (NOSI): Implementation of Clinical Care Guidelines on Opioid Prescribing for Pain Management. See Notice [NOT-DA-20-038](#).
- **December 11, 2020** - Notice of Special Interest (NOSI): Tailoring Follow-up Care for Survivors Using Risk-Stratified Pathways. See Notice [NOT-CA-21-019](#).
- **October 26, 2020** - Notice of Special Interest (NOSI): Use of Predictive Analytics to Accelerate Late-Stage Implementation Research to Address Heart, Lung, Blood, and Sleep Disorders. See Notice [NOT-HL-20-815](#).
- **May 19, 2020** - Notice of Special Interest (NOSI): Development and Preliminary Testing of Health-related Behavioral Interventions. See Notice [NOT-OD-20-106](#).
- **April 29, 2020** - Notice of Special Interest (NOSI): Heart, lung, blood and sleep focused ancillary studies to large ongoing clinical trials. See Notice [NOT-HL-20-755](#).
- **March 10, 2020** - Reminder: FORMS-F Grant Application Forms & Instructions Must be Used for Due Dates On or After May 25, 2020- New Grant Application Instructions Now Available. See Notice [NOT-OD-20-077](#).
- **February 10, 2020** - Notice of Special Interest (NOSI): Dissemination and Implementation Science for Cancer Prevention and Control in Low Resource Environments. See Notice [NOT-CA-20-025](#).
- **January 6, 2020** - Notice of Special Interest (NOSI): De-implementation of Ineffective or Low-value Clinical Practices along the Cancer Care Continuum. See Notice [NOT-CA-20-021](#).
- **September 4, 2019** - Notice of Change to Information relevant to Specific Institutes/Centers in PAR-19-274. See Notice [NOT-AR-19-040](#).
- **August 23, 2019** - Clarifying Competing Application Instructions and Notice of Publication of Frequently Asked Questions (FAQs) Regarding Proposed Human Fetal Tissue Research. See Notice [NOT-OD-19-137](#).
- **July 26, 2019** - Changes to NIH Requirements Regarding Proposed Human Fetal Tissue Research. See Notice [NOT-OD-19-128](#).

Funding Opportunity Announcement (FOA) Number

PAR-19-274

Companion Funding Opportunity

[PAR-19-275, R21](#) Exploratory/Developmental Grant

[PAR-19-276, R03](#) Small Grant Program

Purpose

“...to support innovative approaches to identifying, understanding, and developing strategies for overcoming barriers to the adoption, adaptation, integration, scale-up and sustainability of evidence-based interventions, tools, policies, and guidelines. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce (“de-implement”) the use of interventions that are ineffective, unproven, low-value, or harmful. In addition, studies to advance dissemination and implementation research methods and measures are encouraged.”

Source: PAR-19-274

Selected research questions

- What **factors influence the creation, packaging, transmission and reception** of valid health research knowledge?
- How can an evidence-based practice be **adapted** to fit within specific contexts or settings?
- Which **strategies** best support uptake and sustainability, and how do these strategies work?
- How do you **scale up and sustain** effective interventions across systems, states and communities
- How do you **de-implement** practices that are not evidence-based, or are harmful or wasteful?

SAMPLE GRANT APPLICATIONS

R01: Implementing Tobacco Use Treatment Guidelines in Community Health Centers in Vietnam

Principal Investigator



Donna Shelley, MD, MPH
NEW YORK UNIVERSITY*

FOA**

PAR 13-055

Award Number

R01#CA175329-01A1

[View Funded Grant \(PDF, 2.21MB\)](#)

R01: De-implementation of low value castration for men with prostate cancer

Principal Investigator



Ted Skolarus, MD, MPH, FACS
UNIVERSITY OF MICHIGAN AT ANN
ARBOR*

FOA**

PAR 16-238

Award Number

R37#CA222885-01

[View Funded Grant \(PDF, 828.73KB\)](#)

R01: Disseminating an Evidence-Based Tobacco Control Intervention for School Teachers in India

Principal Investigator



Glorian Sorenson, PhD, MPH
HARVARD SCHOOL OF PUBLIC
HEALTH*

FOA**

PAR 13-055

Award Number

R01#CA200691-01A1

[View Funded Grant \(PDF, 1.26MB\)](#)

R21: Effective Training Models for Implementing Health-Promoting Practices Afterschool

Principal Investigator



Rebekka Maighread Lee, ScD
HARVARD SCHOOL OF PUBLIC
HEALTH*

FOA**

PAR 13-054

Award Number

R21#CA201567-01A1

[View Funded Grant \(PDF, 836.74KB\)](#)

BUDGET
PROPOSAL

LEADING THE
NATION'S PROGRESS

ENVISIONING
THE FUTURE

IMMUNE SYSTEM
& CANCER

ARTIFICIAL
INTELLIGENCE

IMPLEMENTATION
SCIENCE

STRENGTHENING THE
RESEARCH ENTERPRISE



The field of implementation science bridges the divide between research and practice to improve patient and population health outcomes.

Global Implementation Science

The Center for Global Health (CGH) at the US National Cancer Institute (NCI) was established in 2011 to contribute to improved cancer control worldwide. Coincident with the CGH 10th anniversary in 2021, [this strategic plan](#) will inform activities for the five-year period of 2021–2025.

CGH supports the NCI mission by advancing global cancer research and coordinating NCI engagement in global cancer control. CGH also represents NCI in international research partnerships, playing a key role in coordinating multinational research efforts for global benefit. Core values for CGH are impact, equity, and collaboration. These values inform CGH efforts to lead innovative, impactful programs with partners within and outside NCI. CGH goals are focused on research, research training, dissemination, and partnership, primarily in low- and middle-income countries (LMICs).

Areas of scientific focus include new technologies, [implementation science](#), cancer health disparities, clinical trials, and cancer etiology. Each of these areas require CGH to leverage expertise and resources across NCI divisions, offices, and centers



CGH Strategic Plan

This plan will inform activities for the Center for Global Health for 2021–2025.

Global Implementation Science Funding Opportunities

- **Notice of Special Interest (NOSI): Dissemination and Implementation Science for Cancer Prevention and Control in Low Resource Environments**
 - [NOT-CA-20-025](#) (Must apply through DIRH PARs)
- **Implementation Science for Cancer Control in People Living with HIV in Low- and Middle-Income Countries (U01 Clinical Trial Optional)**
 - [RFA-CA-21-056](#)

Filters

- Research Categories
- Basic Biobehavioral and Psychological Sciences
- Behavioral Research
- Cancer Survivorship
- Epidemiology and Genomics Research
- Health Communication and Informatics Research
- Health Disparities
- Healthcare Delivery Research
- Implementation Science
- Parent and Omnibus Funding Announcements
- Surveillance Research
- Tobacco Control Research

Type of Funding

Activity Code

Type of Research

Clear Filters

Enter search terms here... 🔍

Export To Excel Email Results Print Results

Showing 1-10 of 13 (filtered from 116 total entries)

Results per page: 10

Title	Announcement Number	Code	Clinical Research	Expires	Contact
Increasing Uptake of Evidence-Based Screening In Diverse Adult Populations	PA-18-932	R01	Clinical Trial Optional	January 08, 2022	Erica Breslau 240-276-6773 breslaue@mail.nih.gov
Social and Behavioral Intervention Research to Address Modifiable Risk Factors for Cancer in Rural Populations	RFA-CA-20-051	R01	Clinical Trial Required	January 19, 2022	Kelly Blake 240-281-5934 kelly.blake@nih.gov
Dissemination and Implementation Research in Health (Domestic and International Funding Opportunity)	PAR-19-276	R03		May 08, 2022	Gila Neta 240-276-6785 neta.gil@mail.nih.gov Cynthia A. Vinson 240-276-6745 cvinson@mail.nih.gov
Dissemination and Implementation Research in Health (Domestic and International Funding Opportunity)	PAR-19-275	R21	Clinical Trial Optional	May 08, 2022	Gila Neta 240-276-6785 neta.gil@mail.nih.gov Cynthia A. Vinson 240-276-6745 cvinson@mail.nih.gov
Dissemination and Implementation Research in Health (Domestic and International Funding Opportunity)	PAR-19-274	R01	Clinical Trial Optional	May 08, 2022	Gila Neta 240-276-6785 neta.gil@mail.nih.gov Cynthia A. Vinson 240-276-6745 cvinson@mail.nih.gov
Notice of Special Interest (NOSI): De-implementation of Ineffective or Low-value Clinical Practices along the Cancer Care Continuum	NOT-CA-20-021			May 10, 2022	Erica Breslau 240-276-6773 breslaue@mail.nih.gov Wynne E. Norton 240-276-6875 wynne.norton@nih.gov
Linking the Provider Recommendation to Adolescent HPV Vaccine Uptake	PAR-19-359	R03	Clinical Trial Optional	July 17, 2022	Sarah Kobrin 240-276-6991

NCI-Specific Opportunities

Training Institute for Dissemination and Implementation Research in Cancer (TIDIRC) OpenAccess

[Implementation Science](#) / [Training & Events](#) / [Training in Cancer](#) / [TIDIRC OpenAccess](#)



The eight modules below make up the TIDIRC OpenAccess course. These modules can be viewed together as a whole or individually by section. Before starting the course trainees should create a Dissemination & Implementation (D&I) research project idea. From there Trainees can move through the modules to build up their project idea. These eight modules include videos, readings, and self-reflection questions. After completing the modules, trainees can workshop their proposed projects using what they've learned.

We are grateful to the lecturers for their efforts and for allowing us to provide this important resource to the community.

The course includes eight modules and a final assignment:

Module 1: Introduction to Dissemination & Implementation Science

Module 2: Implementation Science Theories, Models & Frameworks

Module 3: Implementation Science Measures

Module 4: Study Designs in Implementation Science

Module 5: Research Approaches in Implementation Science

Module 6: Implementation Strategies

Module 7: Adaptation & Fidelity of Interventions in Implementation Science

Module 8: Emerging Topics in Implementation Science

Consortium for Cancer Implementation Science (CCIS)

[Implementation Science](#) / [Initiatives](#) / [Consortium for Cancer Implementation Science \(CCIS\)](#)



The Consortium for Cancer Implementation Science (CCIS) focuses on cancer control priorities, cross-collaboration, and innovative solutions in implementation science (IS). CCIS seeks to develop a new approach for the field to work together to address key challenges and identify and develop new areas of investigation toward advancing the IS agenda in cancer control.

CCIS DEVELOPMENT OF PUBLIC GOODS

To support the ongoing efforts of the Consortium for Cancer Implementation Science a collection of public goods, widely available tools and resources, have been developed by the action groups to address key challenges and advance the implementation science agenda in cancer.

[Learn More](#)

THIRD ANNUAL CCIS MEETING - OCTOBER 6-7, 2021

The 2021 CCIS meeting focused on lessons learned in IS from COVID-19, and re-emerging and moving forward from the pandemic. The event featured a variety of presentations and discussion sessions, as well as pre-work to encourage more engagement and discussion during each virtual session meeting.

[Learn More](#)

CCIS Public Goods

Implementation Science / Initiatives / Consortium for Cancer Implementation Science (CCIS) / Public Goods

SECTION MENU

Call for Proposals

Application Procedure

Eligibility Requirements

Frequently Asked Questions

Public Goods

To support the ongoing efforts of the Consortium for Cancer Implementation Science a collection of public goods, widely available tools and resources, have been developed by the action groups to address key challenges and advance the implementation science agenda in cancer.

+ Community Participation in Implementation Science

+ Economics and Cost in Implementation Science

+ Policy and Implementation Science

Members of the Context and Equity in implementation Science, Implementation in Global Health, Implementation of Multilevel Interventions, Implementation Science Study Design, Learning Healthcare Systems as Natural Laboratories, and Technology and Health Communication in Implementation Science action groups will have publicly available resources in the coming years.

Read the [August 2021 IS Blog](#) to learn more about the themes from 2020 CCIS action groups.

Things to Remember

- Start early
- Need prior approval to exceed \$500K for R01
- Do not skimp on methods/approach
- Demonstrate your partnership(s) and understanding of context
- TALK WITH PROGRAM OFFICERS – A listing of Institute contacts available at the end of Funding Opportunities.
- Question about Review: Wenjuan Wang, PhD, CSR

Guidance on Reaching out to Program Officers

- Identify Program Officer from FOA lists
- Send them one-pager (Specific Aims page)
- Highlight questions
- Ask for 30-minute call?
- Don't be shy to email reminders (weekly, not daily)

A dirt road splits into two paths leading towards a bright sunset over a grassy field. The sun is low on the horizon, creating a golden glow and casting long shadows. The sky is filled with scattered clouds, some of which are illuminated by the setting sun. The overall scene is peaceful and evocative of a journey or a choice.

Thank you!
Gila.Neta@nih.gov



**NATIONAL
CANCER
INSTITUTE**

www.cancer.gov

www.cancer.gov/espanol